AngioDynamics (ANGO) Misses Q2 EPS by 2c; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
AngioDynamics (ANGO) PT Lowered to $34 at Canaccord Genuity
January 7, 2022 7:21 AM ESTCanaccord Genuity analyst William Plovanic lowered the price target on AngioDynamics (NASDAQ: ANGO) to $34.00 (from $37.00) while maintaining a Buy rating following results and sector multiple compression.
The analyst commented, "ANGO reported FQ2/22 revenue of $78.3M (+7.6% Y/Y), beating our $77.7M estimate and consensus projection of $77.9M despite building a significant backlog due to manufacturing and shipping delays. ANGOs bottom line missed our... More
